Mineralys Therapeutics (Mineralys Therapeutics) EBIT : $-105.08 Mil (TTM As of Mar. 2024)

View and export this data going back to 2023. Start your Free Trial

What is Mineralys Therapeutics EBIT?

Mineralys Therapeutics's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2024 was $-35.36 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2024 was $-105.08 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Mineralys Therapeutics's annualized ROC % for the quarter that ended in Mar. 2024 was -3,887.00%. Mineralys Therapeutics's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was -13,439.24%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Mineralys Therapeutics's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was -17.26%.

Mineralys Therapeutics EBIT Historical Data

The historical data trend for Mineralys Therapeutics's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mineralys Therapeutics EBIT Chart

Mineralys Therapeutics Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

EBIT

-3.31

-19.38

-31.48

-84.66

Mineralys Therapeutics Quarterly Data
	Dec20	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
EBIT	Get a 7-Day Free Trial							-14.94	-15.74	-26.27	-27.71	-35.36

Competitive Comparison of Mineralys Therapeutics's EBIT

For the Biotechnology subindustry, Mineralys Therapeutics's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Mineralys Therapeutics's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Mineralys Therapeutics's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Mineralys Therapeutics's EV-to-EBIT falls into.

Mineralys Therapeutics EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-105.08 Mil.

Mineralys Therapeutics (NAS:MLYS) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Mineralys Therapeutics's annualized ROC % for the quarter that ended in Mar. 2024 is calculated as:

	ROC % (Q: Mar. 2024 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Dec. 2023 )	+	Invested Capital (Q: Mar. 2024 ))	/ count )
=	-141.448 * ( 1 - 0% )	/	( (6.186	+	1.092)	/ 2 )
=	-141.448	/	3.639
=	-3,887.00 %

where

	Invested Capital		(Q: Dec. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	251.636	-	8.883	-	( 236.567	-	max(0, 10.482	-	249.103	+	236.567	))
=	6.186

	Invested Capital		(Q: Mar. 2024 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	347.249	-	18.542	-	( 338.565	-	max(0, 19.204	-	346.819	+	338.565	))
=	1.092

Note: The Operating Income data used here is four times the quarterly (Mar. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

Mineralys Therapeutics's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Mar. 2024 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Dec. 2023		Q: Mar. 2024
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	-141.448	/	( ( (0 + max(2.054, 0))	+	(0.051 + max(-10.95, 0)) )	/	2 )
=	-141.448	/	( ( 2.054	+	0.051 )	/	2 )
=	-141.448	/	1.0525
=	-13,439.24 %

where Working Capital is:

	Working Capital		(Q: Dec. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	12.536)	-	(8.883	+	0	+	1.599)
=	2.054

	Working Capital		(Q: Mar. 2024 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	8.254)	-	(18.542	+	0	+	0.662)
=	-10.95

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Mineralys Therapeutics's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Mar. 2024 )
	=	-105.081	/	608.803
	=	-17.26 %

Mineralys Therapeutics EBIT Related Terms

Thank you for viewing the detailed overview of Mineralys Therapeutics's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Mineralys Therapeutics (Mineralys Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Mineralys Therapeutics Inc (NAS:MLYS) » Definitions » EBIT

Comparable Companies

Traded in Other Exchanges

N/A

Address

150 North Radnor Chester Road, Suite F200, Radnor, PA, USA, 19087

Website

https://mineralystx.com

Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking three or more antihypertensive medications typically including a diuretic.

Executives

Jon Congleton	director, officer: Chief Executive Officer	3122 STERLING CIRCLE, SUITE 200, BOULDER CO 80301
Glenn Sblendorio	director	3 TIMES SQAURE, 12TH FLOOR, NEW YORK NY 10036
Daphne Karydas	director	35 GATEHOUSE DRIVE, BUILDING D, FLOOR 3, WALTHAM MA 02451
David Malcom Rodman	officer: Chief Medical Officer	3122 STERLING CIRCLE, SUITE 200, BOULDER CO 80301
Ra Capital Healthcare Fund Lp	director, 10 percent owner	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Srinivas Akkaraju	director, 10 percent owner	565 EVERETT AVENUE, PALO ALTO CA 94301
Hbm Healthcare Investments (cayman) Ltd.	10 percent owner	GOVERNORS SQUARE, 23 LIME TREE BAY AVE.,, PO BOX 30852, GRAND CAYMAN E9 KY1-1204
Adam Scott Levy	officer: CFO, Chief Bus. Off. and Secy.	C/O MIRAGEN THERAPEUTICS, INC., 6200 LOOKOUT ROAD, #100, BOULDER CO 80301
Catalys Pacific Fund, Lp	10 percent owner	301 9-19 HACHIYAMA, SHIBUYA, TOKYO M0 150-0035
Olivier Litzka	director	C/O MINERALYS THERAPEUTICS, INC., 150 N. RADNOR CHESTER RD, STE. F200, RADNOR PA 19087
Takeshi Takahashi	director	C/O MINERALYS THERAPEUTICS, INC., 150 N. RADNOR CHESTER RD, STE. F200, RADNOR PA 19087
Brian Taylor Slingsby	director, 10 percent owner	C/O MINERALYS THERAPEUTICS, INC., 150 N. RADNOR CHESTER RD, STE. F200, RADNOR PA 19087
Ra Capital Nexus Fund Iii, L.p.	director, 10 percent owner	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Samsara Biocapital, L.p.	10 percent owner	628 MIDDLEFIELD ROAD, PALO ALTO CA 94301
Alexander Asam	director	C/O ARCUTIS BIOTHERAPEUTICS, INC., 2945 TOWNSGATE ROAD, SUITE 110, WESTLAKE VILLAGE CA 91361